Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Hold” by Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average rating of “Hold” from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $28.90.

A number of brokerages recently issued reports on HIMS. Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a report on Tuesday, February 24th. Citigroup upped their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Barclays upped their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th.

Hims & Hers Health Trading Down 0.2%

Shares of NYSE:HIMS opened at $23.71 on Monday. The stock has a market capitalization of $5.40 billion, a PE ratio of -263.46, a P/E/G ratio of 46.09 and a beta of 2.43. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43. The firm has a fifty day moving average price of $24.04 and a 200 day moving average price of $27.98. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share. Analysts expect that Hims & Hers Health will post 0.04 EPS for the current fiscal year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched generic semaglutide in Canada, giving it first-time international access to the fast-growing GLP-1 market and potentially boosting future sales. Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
• Positive Sentiment: The company is expanding its personalized care platform with labs, hormone programs, and broader global ambitions, which suggests a larger long-term addressable market. Hims & Hers Deepens Personalized Care Through Platform Expansion
• Positive Sentiment: Analyst coverage turned slightly more constructive after Truist raised its price target to $23 from $18, even though the rating remained Hold. Truist Raises Hims & Hers Price Target
• Neutral Sentiment: Additional coverage noted the Canada GLP-1 launch and broader platform expansion, reinforcing investor attention on growth initiatives rather than new financial results. Reuters Canada semaglutide article
• Negative Sentiment: Some commentary remains cautious after the recent earnings miss and sharp prior pullback, reminding investors that execution risk and valuation concerns are still in focus. MarketBeat earnings miss analysis

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,950 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares of the company’s stock, valued at $216,086.88. This represents a 38.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 212,807 shares of company stock valued at $5,473,644. Company insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Pathway Capital Management LP bought a new stake in Hims & Hers Health during the third quarter valued at about $6,766,000. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the last quarter. BIT Capital GmbH raised its position in shares of Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after buying an additional 938,728 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after buying an additional 678,600 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Hims & Hers Health by 25.6% during the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after buying an additional 75,679 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.